IP Library › Granted Patent US 12,496,301
Granted Patent B2
US 12,496,301 · App. 18/972,606 · Granted Dec 16, 2025

Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Inventors: Dan Sherman (Madison, CT); James Alan Gregory (New Haven, CT)
Assignee: Arvinas Operations, Inc.
A61K31/506
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,301
App. No.
18/972,606
Granted
Dec 16, 2025
Kind
B2
Abstract

This disclosure pertains to methods of treating or preventing spinal and bulbar muscular atrophy (SBMA), or one or more symptoms of SBMA, wherein the method comprises administering to a subject in need thereof an effective amount of Compound A, or a pharmaceutically acceptable salt thereof.

Claims (34)

1 . A method of treating spinal and bulbar muscular atrophy (SBMA) in a subject in need thereof, comprising administering to the subject an effective amount of Compound A:

or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject orally.

3 . The method of claim 1 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject once a day, once every two days, once every three days, or once every four days.

4 . A method of treating spinal and bulbar muscular atrophy (SBMA) in a subject in need thereof, comprising administering to the subject about 1 mg to about 500 mg of Compound A:

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject orally.

6 . The method of claim 4 , wherein about 5 mg to about 400 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

7 . The method of claim 4 , wherein about 10 mg to about 350 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

8 . The method of claim 4 , wherein about 15 mg to about 300 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

9 . The method of claim 4 , wherein about 20 mg to about 250 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

10 . The method of claim 4 , wherein about 25 mg to about 200 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

11 . The method of claim 4 , wherein about 75 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

12 . The method of claim 4 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject in one of the following amounts: about 25 mg to about 75 mg, about 30 mg to about 80 mg, about 35 mg to about 85 mg, about 40 mg to about 90 mg, about 45 mg to about 95 mg, about 50 mg to about 100 mg, about 55 mg to about 105 mg, about 60 mg to about 110 mg, about 65 mg to about 115 mg, about 70 mg to about 120 mg, or about 75 mg to about 125 mg.

13 . The method of claim 4 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject in one of the following amounts: about 200 mg to about 500 mg, about 200 mg to about 450 mg, about 200 mg to about 400 mg, about 200 mg to about 350 mg, about 200 mg to about 300 mg, or about 200 mg to about 250 mg.

14 . The method of claim 4 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject once a day, once every two days, once every three days, or once every four days.

15 . A method of treating a symptom of spinal and bulbar muscular atrophy (SBMA) in a subject in need thereof, comprising administering to the subject an effective amount of Compound A:

or a pharmaceutically acceptable salt thereof.

16 . The method of claim 15 , wherein the symptom of SBMA is fatigue, muscle cramps, weakness in the limbs, difficulty in chewing, difficulty in swallowing, difficulty speaking, diminished deep tendon reflexes, lack of pathological reflexes, diminished vibration sensation in legs, erectile dysfunction, reduced fertility, gynecomastia, testicular atrophy, glucose resistance, hyperlipidemia, fatty liver disease, or a combination thereof.

17 . The method of claim 15 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject orally.

18 . The method of claim 15 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject once a day, once every two days, once every three days, or once every four days.

19 . A method of treating a symptom of spinal and bulbar muscular atrophy (SBMA) in a subject in need thereof, comprising administering to the subject about 1 mg to about 500 mg of Compound A:

or a pharmaceutically acceptable salt thereof.

20 . The method of claim 19 , wherein the symptom of SBMA is fatigue, muscle cramps, weakness in the limbs, difficulty in chewing, difficulty in swallowing, difficulty speaking, diminished deep tendon reflexes, lack of pathological reflexes, diminished vibration sensation in legs, erectile dysfunction, reduced fertility, gynecomastia, testicular atrophy, glucose resistance, hyperlipidemia, fatty liver disease, or a combination thereof.

21 . The method of claim 19 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject orally.

22 . The method of claim 19 , wherein about 5 mg to about 400 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

23 . The method of claim 19 , wherein about 10 mg to about 350 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

24 . The method of claim 19 , wherein about 15 mg to about 300 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

25 . The method of claim 19 , wherein about 20 mg to about 250 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

26 . The method of claim 19 , wherein about 25 mg to about 200 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

27 . The method of claim 19 , wherein about 75 mg of Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject.

28 . The method of claim 19 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject in one of the following amounts: about 25 mg to about 75 mg, about 30 mg to about 80 mg, about 35 mg to about 85 mg, about 40 mg to about 90 mg, about 45 mg to about 95 mg, about 50 mg to about 100 mg, about 55 mg to about 105 mg, about 60 mg to about 110 mg, about 65 mg to about 115 mg, about 70 mg to about 120 mg, or about 75 mg to about 125 mg.

29 . The method of claim 19 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject in one of the following amounts: about 200 mg to about 500 mg, about 200 mg to about 450 mg, about 200 mg to about 400 mg, about 200 mg to about 350 mg, about 200 mg to about 300 mg, or about 200 mg to about 250 mg.

30 . The method of claim 19 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered to the subject once a day, once every two days, once every three days, or once every four days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2025
From: SHERMAN, DAN; GREGORY, JAMES ALAN
To: ARVINAS OPERATIONS, INC.
Reel/Frame 071900/0894 →
Continuity (2)
Provisional Application 63608071 · Dec 8, 2023
Related Publication 20250186440A1 · Jun 12, 2025
References Cited (381)
US 6306663B1 · Kenton et al. · 2001 [cited by applicant]
US 6670348B1 · Rosen et al. · 2003 [cited by applicant]
US 7030141B2 · Bigge et al. · 2006 [cited by applicant]
US 7041298B2 · Deshaies et al. · 2006 [cited by applicant]
US 7109219B2 · Tsuruoka et al. · 2006 [cited by applicant]
US 7153867B2 · Shah et al. · 2006 [cited by applicant]
US 7208157B2 · Sakamoto et al. · 2007 [cited by applicant]
US 7468380B2 · Tsuruoka et al. · 2008 [cited by applicant]
US 8012997B2 · Robarge et al. · 2011 [cited by applicant]
US 8481568B2 · Muller et al. · 2013 [cited by applicant]
US 8765176B2 · Yamamoto et al. · 2014 [cited by applicant]
US 8921378B2 · Törmäkangas et al. · 2014 [cited by applicant]
US 9500653B2 · Crews et al. · 2016 [cited by applicant]
US 9632089B2 · Crews et al. · 2017 [cited by applicant]
US 9796698B2 · Muller et al. · 2017 [cited by applicant]
US 9801868B2 · Muller et al. · 2017 [cited by applicant]
US 10047151B2 · Lopez-Girona et al. · 2018 [cited by applicant]
US 10118933B2 · Wohlfahrt et al. · 2018 [cited by applicant]
US 10584101B2 · Crew · 2020 [cited by applicant]
US 10844021B2 · Crew et al. · 2020 [cited by applicant]
US 11149007B2 · Ammirante et al. · 2021 [cited by applicant]
US 11236051B2 · Crew et al. · 2022 [cited by applicant]
US 11312702B2 · Fan et al. · 2022 [cited by applicant]
US 11325889B2 · Ammirante et al. · 2022 [cited by applicant]
US 11420956B2 · Fan et al. · 2022 [cited by applicant]
US 11535606B2 · Fan et al. · 2022 [cited by applicant]
US 11560371B2 · Alexander et al. · 2023 [cited by applicant]
US 11634407B2 · Alexander et al. · 2023 [cited by applicant]
US 11660267B2 · Coric et al. · 2023 [cited by applicant]
US 11739075B2 · Alexander et al. · 2023 [cited by applicant]
US 11952347B2 · Crew et al. · 2024 [cited by applicant]
US 11964945B2 · Crew et al. · 2024 [cited by applicant]
US 12043612B2 · Allan et al. · 2024 [cited by applicant]
US 12077509B2 · Berlin et al. · 2024 [cited by applicant]
US 20070254933A1 · Jung et al. · 2007 [cited by applicant]
US 20080051432A1 · Zhang · 2008 [cited by applicant]
US 20080214501A1 · Zhengying et al. · 2008 [cited by applicant]
US 20090035362A1 · Shih et al. · 2009 [cited by applicant]
US 20090142297A1 · Muller et al. · 2009 [cited by applicant]
US 20100048517A1 · Hu et al. · 2010 [cited by applicant]
US 20110196150A1 · Man et al. · 2011 [cited by applicant]
US 20120270800A1 · Verdine et al. · 2012 [cited by applicant]
US 20140079636A1 · Chimmanamada et al. · 2014 [cited by applicant]
US 20140302523A1 · Crews et al. · 2014 [cited by applicant]
US 20140356322A1 · Crews et al. · 2014 [cited by applicant]
US 20150119435A1 · Crews et al. · 2015 [cited by applicant]
US 20150291562A1 · Crew et al. · 2015 [cited by applicant]
US 20150344473A1 · Du et al. · 2015 [cited by applicant]
US 20160022642A1 · Crews et al. · 2016 [cited by applicant]
US 20160045607A1 · Crew et al. · 2016 [cited by applicant]
US 20160058872A1 · Crew et al. · 2016 [cited by applicant]
US 20160136230A1 · Campos et al. · 2016 [cited by applicant]
US 20160214972A1 · Jin et al. · 2016 [cited by applicant]
US 20160243247A1 · Bradner et al. · 2016 [cited by applicant]
US 20160272639A1 · Crew et al. · 2016 [cited by applicant]
US 20160304450A1 · Liang et al. · 2016 [cited by applicant]
US 20160368911A1 · Campos et al. · 2016 [cited by applicant]
US 20170008904A1 · Crew et al. · 2017 [cited by applicant]
US 20170037004A1 · Crew et al. · 2017 [cited by applicant]
US 20170065719A1 · Qian et al. · 2017 [cited by applicant]
US 20170121321A1 · Crews et al. · 2017 [cited by applicant]
US 20170281784A1 · Wang et al. · 2017 [cited by applicant]
US 20170307614A1 · Crews et al. · 2017 [cited by applicant]
US 20170327469A1 · Crew et al. · 2017 [cited by applicant]
US 20180015087A1 · Liu et al. · 2018 [cited by applicant]
US 20180072711A1 · Crew et al. · 2018 [cited by applicant]
US 20180099940A1 · Crew · 2018 [cited by examiner]
US 20180134684A1 · Bradner et al. · 2018 [cited by applicant]
US 20180228907A1 · Crew et al. · 2018 [cited by applicant]
US 20200095205A1 · Crew et al. · 2020 [cited by applicant]
US 20200155689A1 · Crew et al. · 2020 [cited by applicant]
US 20200155690A1 · Crew et al. · 2020 [cited by applicant]
US 20210009528A1 · Crew et al. · 2021 [cited by applicant]
US 20210040044A1 · Crew et al. · 2021 [cited by applicant]
US 20210087170A1 · Fan et al. · 2021 [cited by applicant]
US 20210113557A1 · Crew et al. · 2021 [cited by applicant]
US 20210171470A1 · Crew et al. · 2021 [cited by applicant]
US 20210353621A1 · Peck et al. · 2021 [cited by applicant]
US 20220089570A1 · Crew et al. · 2022 [cited by applicant]
US 20220144809A1 · Dong et al. · 2022 [cited by applicant]
US 20220184078A1 · Chirnomas et al. · 2022 [cited by applicant]
US 20220220124A1 · Fan et al. · 2022 [cited by applicant]
US 20220227771A1 · Fu et al. · 2022 [cited by applicant]
US 20220257774A1 · Du et al. · 2022 [cited by applicant]
US 20220259154A1 · Berlin et al. · 2022 [cited by applicant]
US 20220313826A1 · Phillips et al. · 2022 [cited by applicant]
US 20220372016A1 · Phillips et al. · 2022 [cited by applicant]
US 20220380368A1 · Wang et al. · 2022 [cited by applicant]
US 20230002321A1 · Ammirante et al. · 2023 [cited by applicant]
US 20230012321A1 · Allan et al. · 2023 [cited by applicant]
US 20230082997A1 · Berlin et al. · 2023 [cited by applicant]
US 20230084249A1 · Berlin et al. · 2023 [cited by applicant]
US 20230111119A1 · Lu et al. · 2023 [cited by applicant]
US 20230128132A1 · Crew et al. · 2023 [cited by applicant]
US 20230241227A1 · Desantis et al. · 2023 [cited by applicant]
US 20230242509A1 · Alexander et al. · 2023 [cited by applicant]
US 20230302014A1 · Zhou et al. · 2023 [cited by applicant]
US 20230331681A1 · Berlin et al. · 2023 [cited by applicant]
US 20240002360A1 · Desantis et al. · 2024 [cited by applicant]
US 20240066032A1 · Chirnomas · 2024 [cited by applicant]
US 20240299366A1 · Crew · 2024 [cited by applicant]
US 20250034096A1 · Berlin et al. · 2025 [cited by applicant]
CA 2945975A1 · 2015 [cited by applicant]
CN 1844118A · 2006 [cited by applicant]
CN 103688176A · 2014 [cited by applicant]
CN 110506039A · 2019 [cited by applicant]
CN 110746399A · 2020 [cited by applicant]
CN 111825657A · 2020 [cited by applicant]
CN 113582974A · 2021 [cited by applicant]
CN 113912589A · 2022 [cited by applicant]
CN 114133379A · 2022 [cited by applicant]
CN 114163444A · 2022 [cited by applicant]
CN 114853846A · 2022 [cited by applicant]
CN 116891457A · 2023 [cited by applicant]
CN 117024390A · 2023 [cited by applicant]
CN 112574278A · 2024 [cited by applicant]
EP 2985285 · 2016 [cited by applicant]
EP 3660004A1 · 2020 [cited by applicant]
EP 3971176 · 2022 [cited by applicant]
EP 4023649 · 2022 [cited by applicant]
JP 2004525889A · 2004 [cited by applicant]
JP 2010502627A · 2010 [cited by applicant]
JP 2013508447A · 2013 [cited by applicant]
JP 2014511895A · 2014 [cited by applicant]
JP 7061135B2 · 2022 [cited by applicant]
KR 101859074B1 · 2018 [cited by applicant]
KR 102119465B1 · 2020 [cited by applicant]
RU 2298554C2 · 2007 [cited by applicant]
RU 2310651C2 · 2007 [cited by applicant]
RU 2008112221A · 2009 [cited by applicant]
RU 2448101C2 · 2012 [cited by applicant]
RU 2011121567A · 2012 [cited by applicant]
RU 2012138709A · 2014 [cited by applicant]
WO WO1998003502A1 · 1998 [cited by applicant]
WO WO1999031061A1 · 1999 [cited by applicant]
WO WO2000066119A1 · 2000 [cited by applicant]
WO WO2002000617A2 · 2002 [cited by applicant]
WO WO2002066512A1 · 2002 [cited by applicant]
WO WO2002100845A1 · 2002 [cited by applicant]
WO WO2006113942A2 · 2006 [cited by applicant]
WO WO2007106670A2 · 2007 [cited by applicant]
WO WO2008011392A2 · 2008 [cited by applicant]
WO WO2009015254A1 · 2009 [cited by applicant]
WO WO2010053732A1 · 2010 [cited by applicant]
WO WO2010141805A1 · 2010 [cited by applicant]
WO WO2011008260A2 · 2011 [cited by applicant]
WO WO2012003281A2 · 2012 [cited by applicant]
WO WO2012040527A2 · 2012 [cited by applicant]
WO WO2012078559A2 · 2012 [cited by applicant]
WO WO2012090104A1 · 2012 [cited by applicant]
WO WO2013106643A2 · 2013 [cited by applicant]
WO WO2013106646A2 · 2013 [cited by applicant]
WO WO2013170147A1 · 2013 [cited by applicant]
WO WO2014015157A2 · 2014 [cited by applicant]
WO WO2014108452A1 · 2014 [cited by applicant]
WO WO2014123418A1 · 2014 [cited by applicant]
WO WO2015000868A1 · 2015 [cited by applicant]
WO WO2015038649A1 · 2015 [cited by applicant]
WO WO2015114314A1 · 2015 [cited by applicant]
WO WO2015134464A2 · 2015 [cited by applicant]
WO WO2015160845A2 · 2015 [cited by applicant]
WO WO2016105518A1 · 2016 [cited by applicant]
WO WO2016118666A1 · 2016 [cited by applicant]
WO WO2016146985A1 · 2016 [cited by applicant]
WO WO2016169989A1 · 2016 [cited by applicant]
WO WO2016172134A2 · 2016 [cited by applicant]
WO WO2016197032A1 · 2016 [cited by applicant]
WO WO2016197114A1 · 2016 [cited by applicant]
WO WO2017011590A1 · 2017 [cited by applicant]
WO WO2017030814A1 · 2017 [cited by applicant]
WO WO2017079267A1 · 2017 [cited by applicant]
WO WO2017184995A1 · 2017 [cited by applicant]
WO WO2017185031A1 · 2017 [cited by applicant]
WO WO2017185034A1 · 2017 [cited by applicant]
WO WO2017197051A1 · 2017 [cited by applicant]
WO WO2017197056A1 · 2017 [cited by applicant]
WO WO2018071606A1 · 2018 [cited by applicant]
WO WO2018098280A1 · 2018 [cited by applicant]
WO WO2018177989A1 · 2018 [cited by applicant]
WO WO2020047487A1 · 2020 [cited by applicant]
WO WO2020132014A1 · 2020 [cited by applicant]
WO WO2020132016A1 · 2020 [cited by applicant]
WO WO2020198711A1 · 2020 [cited by applicant]
WO WO2020198712A1 · 2020 [cited by applicant]
WO WO2020211822A1 · 2020 [cited by applicant]
WO WO2021081108A1 · 2021 [cited by applicant]
WO WO2021231174A1 · 2021 [cited by applicant]
WO WO2021231431A1 · 2021 [cited by applicant]
WO WO2021249534A1 · 2021 [cited by applicant]
WO WO2022031642A2 · 2022 [cited by applicant]
WO WO2022048605A1 · 2022 [cited by applicant]
WO WO2022111526A1 · 2022 [cited by applicant]
WO WO2022125969A1 · 2022 [cited by applicant]
WO WO2022187419A1 · 2022 [cited by applicant]
WO WO2022192481A1 · 2022 [cited by applicant]
WO WO2023205481A1 · 2023 [cited by applicant]
WO WO2023222011A1 · 2023 [cited by applicant]
WO WO2024159052A1 · 2024 [cited by applicant]
WO WO2024188209A1 · 2024 [cited by applicant]
WO WO2024197429A1 · 2024 [cited by applicant]
WO WO2024220926A1 · 2024 [cited by applicant]
WO WO2024233696A1 · 2024 [cited by applicant]
WO WO2024245443A1 · 2024 [cited by applicant]
WO WO2025011623A1 · 2025 [cited by applicant]
WO WO2025036269A1 · 2025 [cited by applicant]
WO WO2025036489A1 · 2025 [cited by applicant]
WO WO2025040147A1 · 2025 [cited by applicant]
A. Baniahmad. J Mol Neurosci 58, 343-347 (2016). https://doi.org/10.1007/s12031-015-0681-8. (Year: 2016). [cited by examiner]
Ahn, D., et al., “HIF-1a Peptide Derivatives with modifications at the hydroxyproline residue as activators of HIF-1a”, Bioorganic & Medicinal Chemistry Letters (2009); 19(15): 4403-4405. [cited by applicant]
Allan, G. F., et al., “Therapeutic androgen receptor ligands”, Nuclear Receptor Signaling (2003); 1 (1 ): 1-4. [cited by applicant]
Antonarakis, E. S., “Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer”, Clinical Advances in Hematology and Oncology (2016); 14(5): 316-319. [cited by applicant]
Arvinas, Inc., “Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium”, Press Release (Feb. 17, 2017); 1 page. [cited by applicant]
Asangani, I. A., et al., “Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer”, Nature (2014); 510: 278-282. [cited by applicant]
[Author Unknown] “Abiraterone Mylan (abiraterone acetate)”, European Medicines Agency Science Medicines Health (Aug. 1, 2021) [online] https://www.ema.europa.eu/en/documents/overview/abiraterone-mylan-epar-medicineoverv… [cited by applicant]
[Author Unknown] “Cancer”, Medline Plus Trusted Health Information for You (Apr. 16, 2007) [online] www.nlm.nih.gov/medlineplus/cancer.html (Access Date: Jun. 7, 2007); 10 pages. [cited by applicant]
[Author Unknown] “VCaP” ATCC [Online] https://www.atcc.org/products/crl-2876 (May 19, 2021); 7 pages. [cited by applicant]
Azad, A. A., et al., “Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer”, Clinical Cancer Research (2015); 21 (10): 2315-2324. [cited by applicant]
Bargagna-Mohan, P., et al., “Use of PROTACS as molecular probes of angiogenesis”, Bioorganic & Medicinal Chemistry Letters (2005); 15(11 ): 2724-2727. [cited by applicant]
Beer, T. M., et al., “Enzalutamide in metastatic prostate cancer before chemotherapy”, New England Journal of Medicine (2014); 371 (5): 424-433. [cited by applicant]
Belikov, V.G, “Pharmaceutical Chemistry. Chapter 2.6 Relationship between the chemical structure, properties of substances and their effect on the body”, MEDpress-inform (2007); pp. 27-29; 14 pages with English translat… [cited by applicant]
Berge, S. M., et al., “Pharmaceutical salts”, Journal of Pharmaceutical Sciences (1977); 66(1): 1-19. [cited by applicant]
Bekes, M., et al., “PROTAC targeted protein degraders: the past is prologue”, Nature Reviews Drug Discovery (2022); 21 (3): 181-200. [cited by applicant]
Bondeson, D. P., et al., “Catalytic in vivo protein knockdown by small-molecule PROTACS”, Nature Chemical Biology (2015); 11(8): 611-617. [cited by applicant]
Bondeson, D. P., et al., “Targeted Protein Degradation by Small Molecules”, Annual Review of Pharmacology and Toxicology (2017); 57: 107-123. [cited by applicant]
Bradbury, R. H., et al., “Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer”, Bioorganic & Medicinal Chemistry Letters (2011); 21: 5442-5445. [cited by applicant]
Brittain, H. G. (Ed.), “Polymorphism in Pharmaceutical Solids Second Edition”, Drugs and Pharmaceutical Sciences, CRC Press (2009); vol. 192: 229 pages. [cited by applicant]
Buckley, D., et al., “Small Molecule Inhibitors of the Interaction Between the E3 Ligase VHL and HIF1a”, Angewandte Chemie (International Ed. in English) (Nov. 12, 2012); 51 (46): 11463-11467. [cited by applicant]
Buckley, D. L., et al., “HaloPROTACS: use of small molecule PROTACS to induce degradation of Halo Tag fusion proteins”, ACS Chemical Biology (2015); 10(8): 1831-1837. [cited by applicant]
Buckley, D. L., et al., “Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1 a interaction”, Journal of the American Chemical Society (2012); 134(10): 4465-4468. [cited by applicant]
Burslem, G. M., et al., “Small-Molecule Modulation of Protein Homeostasis”, Chemical Reviews (2017); 117(17): 11269-11301. [cited by applicant]
Caira, M. R., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry (Jan. 1, 1998); 198:163-208. [cited by applicant]
Capitosti, S. M., et al., “Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer”, Bioorganic & Medicinal Chemistry (2004); 12(2): 327-336. [cited by applicant]
Carmony, K. C., et al., “PROTAC-induced proteolytic targeting”, Methods in Molecular Biology (2012); 832: 627-638. [cited by applicant]
Caro-Maldonado, A., et al., “Low-dose statin treatment increases prostate cancer aggressiveness”, Oncotarget (2018); 9(2): 1494-1504. [cited by applicant]
Chevalier-Larsen, E. S., et al., “Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy”, Journal of Neuroscience (2004); … [cited by applicant]
Chirnomas, D., et al., “Protein degraders enter the clinic-a new approach to cancer therapy”, Nature Reviews Clinical Oncology (2023); 20(4): 265-278. DOI: 10.1038/s41571-023-00736-3. [cited by applicant]
ClinicalTrials.gov Identifier: NCT03888612, “Trial of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)” [online] https://clinicaltrials.gov/ct2/show/NCT03888612 (First Posted—Mar. 25, 201… [cited by applicant]
Contino-Pepin, C., et al., “Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application”, Bioorganic & Medicinal Chemistry Letters (2009); 19(3): 878-881. [cited by applicant]
Corson, T. W., et al., “Design and applications of bifunctional small molecules: why two heads are betterthan one”, ACS Chemical Biology (2008); 3(11): 677-692. [cited by applicant]
Crews, C. M., “Targeting the undruggable proteome: the small molecules of my dreams”, Chemistry & Biology (2010); 17(6): 551-555. [cited by applicant]
Cromm, P. M., et al., “Targeted protein degradation: from chemical biology to drug discovery”, Cell chemical Biology (2017); 24(9): 1181-1190. [cited by applicant]
Cyrus, K., et al., “Impact of linker length on the activity of PROTACs”, Molecular Biosystems (2011 ); 7(2): 359-364. [cited by applicant]
Cyrus, K., et al., “Jostling for position: Optimizing linker location in the design of estrogen receptor-targeting PROTACs”, ChemMedChem (2010); 5(7): 979-985. [cited by applicant]
Cyrus, K., et al., “Two-Headed PROTAC: An Effective New Tool for Targeted Protein Degradation”, Chembiochem (2010); 11(11): 1531-1534. [cited by applicant]
Database STN, CAS Registry No. 1004933-70-3, “2-Pyrrolidinecarboxamide, N-(4-bromo-2-fluorophenyl)-4-hydroxy-1-(2-naphthalenylsulfonyl)-, (2S,4R)-”, Chemical Abstracts Service, American Chemical Society; entered Feb. 21… [cited by applicant]
Database STN, CAS Registry No. 1226974-40-8, “Urea, N-[[2-(2,6-dioxo-3-pipe rid inyl)-2,3-d ihydro-1-oxo-1 H-isoindol-5-yl]methyl]-N′-(4-phenylcyclohexyl)-”, Chemical Abstracts Service, American Chemical Society; entere… [cited by applicant]
Database STN, CAS Registry No. 1323403-74-2, “2,4′-Bipyridinium, 1′-[[4-[[[2-(2,6-dioxo-3-piperidinyl)-2 ,3-d ihydro-1-oxo-1 H-isoindol-4-yl]oxy]methyl]phenyl]methyl]-”, Chemical Abstracts Service, American Chemical Soc… [cited by applicant]
Database STN, CAS Registry No. 1323488-76-1, “2,6-Piperidinedione, 3-[4-[[4-[[4-(3,5-difluorophenyl)-1-piperidinyl]methyl]phenyl]methoxy]-1 ,3-dihyd ro-1-oxo-2H-isoindol-2-yl]-”, Chemical Abstracts Service, American Che… [cited by applicant]
Database STN, CAS Registry No. 1323488-78-3, “2,6-Piperidinedione, 3-[4-[[4-[[4-(2,4-difluorophenyl)-1-piperidinyl]methyl]phenyl]methoxy]-1 ,3-dihyd ro-1-oxo-2H-isoindol-2-yl]-, (3S)-”, Chemical Abstracts Service, Ameri… [cited by applicant]
Database STN, CAS Registry No. 155180-53-3, “Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-d imethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 1… [cited by applicant]
Database STN, CAS Registry No. 155255-73-5, “Benzonitrile, 4-[4,4-dimethyl-2,5-d ioxo-3-[ 4-(triphe nylmethoxy) butyl]-1-i mid azol id inyl]-2-(triflu oromethyl)-”, Chemical Abstracts Service, American Chemical Society;… [cited by applicant]
Database STN, CAS Registry No. 1818885-25-4, “Benzamide, N-[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]-4-[[5-[3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-4-yl]amino]propoxy]p… [cited by applicant]
Database STN, CAS Registry No. 186040-53-9, “Benzenepropanoic acid, 13-(benzoylamino)-a-hydroxy-,(2aR,4S,4aS,6R,9S, 11 S, 12S, 12aR, 12bS)-6, 12bbis(a cetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[ 4-cyano-3-(trifluo romethyl) … [cited by applicant]
Database STN, CAS Registry No. 186798-71-0, “Glycinamide, N-[[(triphenylmethyl) thio]acetyl]glycyl-N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-”, Chemical Abstracts Se… [cited by applicant]
Database STN, CAS Registry No. 155255-73-5, “Benzonitrile, 4-[4,4-dimethyl-2,5-d ioxo-3-[ 4-(triphe nylmethoxy) butyl]-1-i mid azol id inyl]-2-(triflu oromethyl)-”, Chemical Abstracts Service, American Chemical Society;… [cited by applicant]
Database STN, CAS Registry No. 186798-85-6, “Benzenepropanamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-4-hydroxy-3,5-diiodo-”, Chemical Abstracts Service, Americ… [cited by applicant]
Database STN, CAS Registry No. 534612-78-7, “Benzonitrile, 4-[3-[5-[4-[[2-[2-(2-methoxyethoxy)ethoxy ]ethyl]su lfonyl]-1-pi perazinyl] pentyl]-4 , 4-d imethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)-”, Chem… [cited by applicant]
Database STN, CAS Registry No. 871986-52-6, “2-Pyrrolidinecarboxamide, N-[(1 S)-3-[ (3aR, 6aS)-5-(2, 6-d imethylbenzoyl) hexahyd ro pyrrolo [3 ,4-c] pyrrol-2( 1 H)-yl]-1-phenylpropyl]-1-(2-furanylcarbonyl)-4-hydroxy-”, … [cited by applicant]
Dyson, G., etal., “Chemistry of Synthetic Drugs”, Moscow, MIR, 1964, pp. 12-19; 25 pages with English machine translation. [cited by applicant]
Ferraldeschi, R., et al., “Targeting the androgen receptor pathway in castrationresistant prostate cancer: progresses and prospects”, Oncogene (2015); 34(14): 1745-1757. [cited by applicant]
Fischer, E. S., et al., “Structure of the DDB1-CRBN E3 Ubiquitin ligase in complex with thalidomide”, Nature (2014); 512(7512): 49-53. [cited by applicant]
Fizazi, K., et al., “Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion tria… [cited by applicant]
Fleisher, D., et al., “Improved oral drug delivery: solubility limitations overcome by the use ofprodrugs”, Advanced Drugs Delivery Reviews (May 1996); 19(2): 115-130. [cited by applicant]
Gadd, M. S., et al., “Structural basis of PROTAC cooperative recognition for selective protein degradation”, Nature Chemical Biology (2017); 13(5): 514-521. [cited by applicant]
Galdeano, C., et al., “Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF)… [cited by applicant]
Gao, X., et al., “Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)”, Journal Of Clinical Oncology 2022 American Society Of Clinical Oncolo… [cited by applicant]
Golub, T. R., et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring”, Science (1999); 286: 531-537. [cited by applicant]
Gosink, M., et al., “Redirecting the specificity of ubiquitination by modifying ubiquitinconjugating enzymes”, Proceedings of the National Academy of Sciences (1995); 92(20): 9117-9121. [cited by applicant]
Guimaraes, T. F., et al., “A multivariate approach applied to quality on particle engineering of spray-dried mannitol”, Advanced Powder Technology (2015); 26(4): 1094-1101. [cited by applicant]
Guo, C., et al., “Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists”, Bioorganic & Medicinal Chemistry Letters (2012); 22: 2572-2578. [cited by applicant]
Guo, C., et al., “Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists”, Journal of Medicinal Chemistry (2011); 54(21): 7693-7704. [cited by applicant]
Gustafson, J. L., et al., “Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging”, Angewandte Chemie (2015); 54: 9659-9662. [cited by applicant]
Ha, S., et al., “A comprehensive overview of small-molecule androgen receptor degraders: Recent progress and future perspectives”, Journal of Medicinal Chemistry (2022); 65(24): 16128-16154. [cited by applicant]
Han, X., et al., “Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer”, Journal of Medicinal Chemistry (2019); 62(2): 941… [cited by applicant]
Heinlein, C. A., et al., “Androgen receptor in prostate cancer”, Endocrine Reviews (2004); 25(2): 276-308. [cited by applicant]
Herberts, C., et al., “Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer,” Nature (2022); 608(7921): 199-208. [cited by applicant]
Hines, J., et al., “Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs”, Proceedings of the National Academy of Sciences (2013); 110(22): 8942-8947. [cited by applicant]
Hon, W., et al., “Structural basis for the recognition of hydroxyproline in HIF-1 a by pVHL”, Nature (2002); 417(6892): 975-978. [cited by applicant]
Huang, X., et al., “Drugging the undruggables: exploring the ubiquitin system for drug development”, Cell Research (2016); 26(4): 484-498. [cited by applicant]
Hughes, S. J., et al., “Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders”, Essays in Biochemistry (2017); 61(5): 505-516. [cited by applicant]
Inacio, P., et al., “FDA Clears Phase 1 Trial of ARV-110 for Advanced Prostate Cancer”, Prostate Cancer News Today (Jan. 30, 2019) [online] https://prostatecancernewstoday.com/2019/01/30/fda-clears-phase-1-trial-arv-110… [cited by applicant]
Ivan, M., et al., “HI Fa targeted for VHL-mediated destruction by praline hydroxylation: implications for 02 sensing”, Science (2001); 292(5516): 464-468. [cited by applicant]
Jang, E. R., et al., “Targeted Degradation of Proteins by PROTACs”, Current Protocols in Chemical Biology (2010); 2(2): 71-87. [cited by applicant]
Jernberg, E., et al., “Clinical relevance of androgen receptor alterations in prostate cancer,” Endocrine Connections (2017); 6: R146-R161. [cited by applicant]
Jung, J., “Human tumor xenografl models for preclinical assessment of anticancer drug development”, Toxicological Research (2014); 30: 1-5. [cited by applicant]
Jung, M. E., et al., “Structure- activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)”, Journal of Medicinal Chemistry (201 O); 53(7): 2779-2796. [cited by applicant]
Khadka, P., et al., “Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability”, Asian Journal of Pharmaceutical Sciences (2014); 9: 304-316. [cited by applicant]
Kharkevich D.A., “Pharmacology/Textbook”, 10th edition, (2010); pp. 72-82; 14 pages with English Summary. [cited by applicant]
Kummerer, K., “Pharmaceuticals in the Environment”, Annual Review of Environment and Resources (2010); 35: 57-75. [cited by applicant]
Knott, E. B., “Compounds containing sulphur chromophores. Part I. The action of bases on heterocyclic sulphide quarternary salts”, Journal of the Chemical Society (Resumed) (1955); 916-927. [cited by applicant]
Knott, E. B., et al., Accession No. 1957:56724, “Compounds containing sulfur chromophores. V. Complex cyanines”, STN (Nov. 24, 2017); 1 page. [cited by applicant]
Knuuttila, M., et al., “Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model”, The American Journal of Patho… [cited by applicant]
Kronke, J., et al., “Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells”, Science (2014); 343(6168): 301-305. [cited by applicant]
Lai, A. C., et al., “Induced protein degradation: an emerging drug discovery paradigm”, Nature Reviews Drug Discovery (2017); 16(2): 101-114. [cited by applicant]
Lai, A. C., et al., “Modular PROTAC design for the degradation of oncogenic BCR-ABL”, Angewandte Chemie International Edition (2016); 55(2): 807-810. [cited by applicant]
Lala, P. K., et al., “Role of nitric oxide in tumor progression: lessons from experimental tumors”, Cancer and Metastasis Reviews (1998); 17: 91-106. [cited by applicant]
Lallous, N., et al., “Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients,” Genome Biology, 2016, 17(10):1-15. [cited by applicant]
Lebraud, H., et al., “Protein degradation by in-cell self-assembly of proteolysis targeting chimeras”, ACS Central Science (2016); 2(12): 927-934. [cited by applicant]
Ledet, E. M., et al., “Comprehensive analysis of AR alterations in circulating tumor DNA from patients with advanced prostate cancer”, The Oncologist (2020); 25(4): 327-333. [cited by applicant]
Lee, B. Y., et al., “FAK signaling in human cancer as a target for therapeutics”, Pharmacology & Therapeutics (2015); 146: 132-149. [cited by applicant]
Lee, H., et al., “Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool”, Chembiochem (2007); 8(17): 2058-2062. [cited by applicant]
Lelais, G., et al., “Discovery of (R, E)-N-(7-Chloro-1-(1-[4-(dimethylamino) but-2-enoyl] azepan-3-yl)-1 H-benzo [d] imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of… [cited by applicant]
Lemmon, M., et al., “Cell signaling by receptor tyrosine kinases”, Cell (2010); 141(7): 1117-1134. [cited by applicant]
Levine, P. M., et al., “Targeting the androgen receptor with steroid conjugates: miniperspective”, Journal of Medicinal Chemistry (2014); 57(20): 8224-8237. [cited by applicant]
Li, S., et al., “IMiD immunomodulatory compounds block C/EBPI3 translation through eIF4E down-regulation resulting in inhibition of MM”, Blood (2011); 117(19): 5157-5165. [cited by applicant]
Li, Y., et al., “Single polymer-drug conjugate carrying two drugs for fixed-dose codelivery”, Medicinal Chemistry (2014); 4(10): 676-683. [cited by applicant]
Liu, K., et al., “Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma”, Organic & Biomolecular Chemistry (2013); 11(29): 4757-4763. [cited by applicant]
Lopez-Girona, A. E. A., et al., “Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide”, Leukemia (2012); 26(11): 2326-2335. [cited by applicant]
Lu, G., et al., “The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins”, Science (2014); 343(6168): 305-309. [cited by applicant]
Lu, J., et al., “Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4”, Chemistry & Biology (2015); 22(6): 755-763. [cited by applicant]
Lu, N. Z., et al., “International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors”, Pharmacolo… [cited by applicant]
Makkonen, H., et al., “Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells”, Molecular and Cellular Endocrinology (2011); 331 (1): 57-65. [cited by applicant]
Maniaci, C., et al., “Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation”, Nature Communications (2017); 8(1): 1-14. [cited by applicant]
Mashkovskiy, M. D., “Medicinal Drugs (Handbook for doctors)”, Moscow “Meditsina” (1993), pp. 5; 4 pages with English translation. [cited by applicant]
Mashkovsky M. D. “Medicaments, Doctor's Manual.” vol. 1, 14th Edition. OOO Novaya Volna, Publisher S.B. Divov. Moscow. (2001), 6 pages with English 181 translation. [cited by applicant]
Min, J., et al., “Structure of an HIF-1 a-pVHL complex: hydroxyproline recognition in signaling”, Science (2002); 296(5574): 1886-1889. [cited by applicant]
Mironov, A. N., editor, “Guidelines for conducting preclinical studies of drugs, Part One”, Moscow: Grif i K (2012); Chapter 39: 640-654; 19 pages with English summary. [cited by applicant]
Mohler, M. L., et al., “Androgen receptor antagonists: a patent review (2008-2011)”, Expert Opinion on Therapeutic Patents (2012); 22(5): 541-565. [cited by applicant]
Morissette, S. L., et al., “High-throughput crystallization: polymorphs, salts, cocrystals and solvates of pharmaceutical solids”, Advanced Drug Delivery Reviews (2004); 56(3): 275-300. [cited by applicant]
Mullard, A., “First targeted protein degrader hits the clinic”, Nature Reviews, Drug Discovery (Apr. 2019); 18: 237-239. [cited by applicant]
Muller, G. W., et al., “Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production”, Bioorganic & Medicinal Chemistry Letters (1999); 9(11): 1625-1630. [cited by applicant]
Navone, N. M., et al., “Establishment of two human prostate cancer cell lines derived from a single bone metastasis”, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research (1997);… [cited by applicant]
Neklesa, T. K. et al., “An oral androgen receptor PROTAC® degrader for prostate cancer”, ASCO Genitourinary Cancers Symposium (2018) [online] https://s3.us-east-1.amazonaws.com/arvinas-assets.investeddigital.com/scienti… [cited by applicant]
Neklesa, T. K. et al., “ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer”, ASCO Genitourinary Cancers Symposium (2019) [online] https://s3.us-east-1.amazonaws.com/arvinas-assets.investeddigital.com… [cited by applicant]
Neklesa, T. K., et al., “Greasy tags for protein removal”, Nature (2012); 487(7407): 308-309. [cited by applicant]
Neklesa, T. K., et al., “Targeted protein degradation by PROTACs”, Pharmacology & Therapeutics (2017); 174: 138-144. [cited by applicant]
Ohoka, N., et al., “SNIPER (TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib”, Cancer Science (2017); 108(5): 1032-1041. [cited by applicant]
Ottis, P., et al., “Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation”, ACS Chemical Biology (2017); 12(10): 2570-2578. [cited by applicant]
Ottis, P., et al., “Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy”, ACS Chemical Biology (2017); 12(4): 892-898. [cited by applicant]
Pepe, A., et al., “Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators”, Journal of Medicinal Chemistry (2013); 56(21): 8280-8297. [cited by applicant]
Polski, A., et al., “The excipients used in the non-coated tablets-a review”, Medicina Internacia Revuo (2014); 102: 10-18. [cited by applicant]
Poon, D. M. C., et al.,“ The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant pro… [cited by applicant]
Poutiainen, P. K., et al., “Design, synthesis, and biological evaluation of nonsteroidal cycloalkane [d] isoxazole-containing androgen receptor modulators”, Journal of Medicinal Chemistry (2012); 55(14): 6316-6327. [cited by applicant]
Prabu, S. L., et al., “Impurities and its importance in pharmacy”, International Journal of Pharmaceutical Sciences Review and Research (201 O); 3(2): 66-71. [cited by applicant]
PubChem CID 118435243, “4-{[5-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1 H-isoindol-4-yl]amino}propoxy)pentyl]oxy}-N-[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide”, National Ce… [cited by applicant]
PubChem CID No. 134414307, “Bavdegalutamide” National Center for Biotechnology Information [online] https://pubchem.ncbi.nlm.nih.gov/compound/134414307; Create date Jun. 23, 2018, 15 pages. [cited by applicant]
Puppala, D., et al., “Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention”, Molecular Pharmacology (2008); 73(4): 1064… [cited by applicant]
Quigley, D. A., et al., “Genomic hallmarks and structural variation in metastatic prostate cancer”, Cell (2018); 174(3): 758-769. [cited by applicant]
Raina, K., et al., “PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer”, Proceedings of the National Academy of Sciences (2016); 113(26): 7124-7129. [cited by applicant]
Raina, K., et al., “Targeted protein knockdown using small molecule degraders”, Current Opinion in Chemical Biology (2017); 39: 46-53. [cited by applicant]
Remillard, D., et al., “Degradation of the BAF complex factor BRD9 by heterobifunctional ligands”, Angewandte Chemie International Edition (2017); 56(21): 5738-5743. [cited by applicant]
Robinson, D., et al., “Integrative clinical genomics of advanced prostate cancer”, Cell (2015); 161 (5): 1215-1228; Erratum in: Cell (2015); 162(2): 452-454. [cited by applicant]
Robinson, R. P., et al., “Discovery of the Hemifumarate and (a-L-Alanyloxy) methyl Ether as Prod rugs of an Antirheumatic Oxindole: Prod rugs for the Enolic OH Group”, Journal of Medicinal Chemistry (1996); 39(1): 10-18. [cited by applicant]
Rodriguez-Gonzalez, A., et al., “Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer”, Oncogene (2008); 27(57): 7201-7211. [cited by applicant]
Romanel, A., et al., “Plasma AR and abiraterone-resistant prostate cancer”, Science Translational Medicine (2015); 7(312): 312re10; 9 pages. [cited by applicant]
Rotili, D., et al., “Photoactivable peptides for identifying enzyme-substrate and protein-protein interactions”, Chemical Communications (2011); 47(5): 1488-1490. [cited by applicant]
Rowe, R. C., et al. (Ed.)., “Handbook of Pharmaceutical Excipients Fifth Edition”, Pharmaceutical Press [online] http://www.gmpua.corn/RD/RD/HandbookPharmaceutical%20Excipients.pdf (2006); 945 pages. [cited by applicant]
Ruchelman, A., et al., “Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity”, Bioorganic & Medicinal Chemistry Letters (2013); 23(1): 360-365. [cited by applicant]
Sakamoto, K. M., et al., “Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation”, Molecular & Cellular Proteomics (2003); 2(12): 1350-1358. [cited by applicant]
Sakamoto, K. M., et al., “Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation”, Proceedings of the National Academy of Sciences (Jul. 2001); 98(15): 8554-… [cited by applicant]
Salami, J., et al., “Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance”, Communications Biology (2018); 1 (100): 1-9. [cited by applicant]
Salami, J., et al., “Waste disposal-An attractive strategy for cancer therapy”, Science (2017); 355(6330): 1163-1167. [cited by applicant]
Sayegh, N., et al., “Recent advances in the management of metastatic prostate cancer”, JCO Oncology Practice (2022); 18(1): 45-55. [cited by applicant]
Schiedel, M., et al., “Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals)”, Journal of Medicinal Chemistry (2018); 61 (2): 482… [cited by applicant]
Schneekloth Jr, J. S., et al., “Chemical genetic control of protein levels: selective in vivo targeted degradation”, Journal of the American Chemical Society (2004); 126(12): 3748-3754. [cited by applicant]
Scudellari, M., “The protein slayers”, Nature (Mar. 21, 2019); 567: 298-300. [cited by applicant]
Shore, N. D., et al., “Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer”, Journal of Clinical Oncology, American Society of C… [cited by applicant]
Siegel, R. L., et al., “Cancer statistics, 2023”, CA: A Cancer Journal for Clinicians (2023); 73(1): 17-48. [cited by applicant]
Smirnova, I. G., et al., “Optical Isomerism and Biological Activity of Medicines”, Moscow University Gazette, Series 2, Chemistry (2012); 53(3): 147-156; 11 pages with English Summary. [cited by applicant]
Smith, A. R., et al., “Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics”, Bioorganic & Medicinal Chemistry Letters (2008); 18(22): 5904-5908. [cited by applicant]
Snaterse, G., et al., “Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids”, Prostate Cancer and Prostatic Diseases (2023); 26(2): 293-301. [cited by applicant]
Stewart, S. G., et al., “Efforts toward elucidating Thalidomide's molecular target: an expedient synthesis of the first Thalidomide biotin analogue”, Organic & Biomolecular Chemistry (2010); 8(18): 4059-4062. [cited by applicant]
Stewart, T. F., et al. “Real-world outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations”, Presented at the European Society for Medic… [cited by applicant]
Stoppler, M. C., “What about surgery for Endometriosis?”, MedicineNet.com [online] http://www.medicinenet.com/endometriosis/article.htm (Retrieved on Apr. 5, 2017); 7 pages. [cited by applicant]
Szajewska, H., “Evidence-based medicine and clinical research: both are needed, neither is perfect”, Annals of Nutrition and Metabolism (2018); 72(3): 13-23. [cited by applicant]
Takeda, D. Y., et al., “A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer”, Cell (2018); 174(2): 422-432, including pp. e1-e6 and Supplemental Figures, 25 total p… [cited by applicant]
Toure, M., et al., “Small-molecule PROTACS: new approaches to protein degradation”, Angewandte Chemie International Edition (2016); 55(6): 1966-1973. [cited by applicant]
Trewartha, D., et al., “Advances in prostate cancer treatment”, Nature Reviews, Drug Discovery (2013); 12(11 ): 823-824. [cited by applicant]
Turk, B. E., et al., “Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production”, Proceedings of the National Academy of Sciences (1996); 93(15): 7552… [cited by applicant]
Van Molle, I., et al., “Dissecting fragment-based lead discovery at the von Hippel-Lindau protein: hypoxia inducible factor 1a protein-protein interface”, Chemistry & Biology (2012); 19(10): 1300-1312. [cited by applicant]
Wesserling, M., et al., “Will In Vitro Tests Replace Animal Models in Experimental Oncology?”, Journal of Tissue Science & Engineering (2011); 2(1): 1-4. [cited by applicant]
Westaby, D., et al., “A new old target: androgen receptor signaling and advanced prostate cancer”, Annual Review of Pharmacology and Toxicology (2022); 62(1): 131-153. [cited by applicant]
Winter, G. E., et al., “Phthalimide conjugation as a strategy for in vivo target protein degradation”, Science (2015); 348(6241): 1376-1381. [cited by applicant]
Wyatt, A. W., et al., “Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer”, JAMA Oncology (2016); 2(12): 1598-1606. [cited by applicant]
Xi, J-Y., et al., “Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery”, Bioorganic Chemistry, Academic Press Inc. (2022); 125(105848); 18 pages. DOI: 10.1016/J.BIOORG.2022.105848. [cited by applicant]
Xiang, W., et al., “Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer”, Journal of Medicinal Chemistry (2021); 64(18): … [cited by applicant]
Zava, D. T., et al., “Androgen receptor assay with [3H] methyltrienolone (R1881) in the presence of progesterone receptors”, Endocrinology (1979); 104(4): 1007-1012. [cited by applicant]
Zengerle, M., et al., “Selective small molecule induced degradation of the BET bromodomain protein BRD4”, ACS Chemical Biology (2015); 10(8): 1770-1777. [cited by applicant]
Zhang, D., et al., “Targeted Degradation of Proteins by Small Molecules: A Novel Tool for Functional Proteomics”, Combinatorial Chemistry & High Throughput Screening (2004); 7(7): 689-697. [cited by applicant]
Zhao, X-Y., et al., “Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor”, Nature Medicine (2000); 6(6): 703-706. [cited by applicant]
Zhulenko, V. N., et al., “Pharmacology”, Moscow, “KolosS” Publishing House (2008); pp. 34-35; 4 pages with English summary. [cited by applicant]